Weekly Digest – 15-21 Apr 2023 Weekly Digest – 15-21 Apr 2023 April 19, 2023: Orelabrutinib (Oral) / Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) / InnoCare: Received NMPA approval in China Orelabrutinib obtained NMPA approval for treating R/R MZL in […]
Weekly Digest – 15-21 Apr 2023 Weekly Digest – 15-21 Apr 2023 April 19, 2023: Polatuzumab vedotin-piiq (IV) / DLBCL / Roche: Received US FDA approval Roche announced US FDA approval of Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab), […]
Weekly Digest – 15-21 Apr 2023 Weekly Digest – 15-21 Apr 2023 April 16, 2023: Durvalumab (IV) / NSCLC / AstraZeneca: Results from Phase 3 AEGEAN study demonstrated prolong event-free survival AstraZeneca reported data from AACR 2023 for Phase 3 […]
Weekly Digest – 15-21 Apr 2023 Weekly Digest – 15-21 Apr 2023 April 16, 2023: Tafasitamab-cxix (IV) / DLBCL / Morphosys / Incyte: 5 Year data from L-MIND study demonstrated prolonged, durable responses MorphoSys and Incyte reported 5-year follow-up data […]
Weekly Digest – 15-21 Apr 2023 Weekly Digest – 15-21 Apr 2023 April 16, 2023: Atezolizumab (IV) + Bevacizumab (IV) / HCC / Genentech / Roche: Phase 3 IMbrave050 study demonstrated reduced risk of cancer recurrence in patients Genentech reported […]
Weekly Digest – 15-21 Apr 2023 Weekly Digest – 15-21 Apr 2023 April 16, 2023: Pembrolizumab (IV) / Biliary Tract Cancer / Merck: Improved OS data from Phase 3 KEYNOTE-966 trial Merck reported positive data from AACR 2023 for KEYNOTE-966 […]
